查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1573162

心血管药物市场：按药物类别、适应症、患者人口统计、最终用户、给药途径、分销管道 - 2025-2030 年全球预测

Cardiovascular Therapeutics Market by Drug Class, Indication, Patient Demographics, End-User, Route of Administration, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年心血管治疗市场价值为473.7亿美元，预计2024年将达到507.1亿美元，复合年增长率为7.48%，预计到2030年将达到785.1亿美元。

心血管药物市场包括各种旨在管理和减轻心臟和血管疾病的治疗方法和药物。由于老化、肥胖和生活方式改变等因素导致心血管疾病的盛行率增加，对有效治疗方法的需求正在迅速增加。随着全球健康意识的提高和医疗技术的进步，推动了药物、手术设备和再生医学的应用，对创新治疗方法的需求也越来越大。典型的最终用户包括医院、诊所、研究机构和製药公司。该领域的成长主要受到技术进步的推动，例如新型疗法、个人化医疗的发展以及微创手术的普及。治疗机会存在于新兴市场的开拓中，这些市场的医疗基础设施正在快速发展，使用人工智慧进行预测分析，以及製定针对患者的治疗计划。公司应专注于策略伙伴关係和研发投资，以利用这些趋势。然而，高昂的开发成本、严格的法规环境以及某些治疗方法的潜在副作用等挑战可能会阻碍成长。某些地区缺乏成本和无法获得先进医疗服务，也阻碍了市场渗透。创新机会包括基因治疗、使用巨量资料分析进行患者分析，以及开发生物可吸收支架和智慧型穿戴装置来监测心血管健康。竞争激烈且快速发展的市场需要市场相关人员不断创新和适应。公司必须注重消费者教育并进行全面的临床试验，以确保安全性和有效性，并开发具有成本效益的解决方案并加强全球影响力。解决这些多方面的挑战将使公司处于心血管药物市场的前沿。

主要市场统计
基准年[2023] 473.7亿美元
预测年份 [2024] 507.1亿美元
预测年份 [2030] 785.1亿美元
复合年增长率（%） 7.48%

市场动态：快速发展的心血管治疗市场的关键市场洞察

供需的动态交互作用正在改变心血管药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 心血管疾病盛行率的增加和人口老化推动了对先进治疗的需求
    • 心血管治疗领域的技术进步与创新推动市场成长
    • 医疗支出的增加和政府的支持政策推动市场扩张
    • 心血管疾病早期诊断和治疗意识的提高推动市场成长
  • 市场限制因素
    • 患者和初级保健提供者对心血管疾病及其治疗的认识和理解较低
    • 与心血管药物相关的副作用和不良反应使患者和医疗保健提供者对采用新疗法犹豫不决
  • 市场机会
    • 透过积极的全球行销策略扩大心血管疾病新型基因疗法的覆盖范围
    • 人工智慧驱动的精准医疗可改善复杂心血管疾病的治疗效果
    • 透过与生技公司的策略联盟加速先锋心血管疗法的开发
  • 市场挑战
    • 复杂的临床试验设计和严格的要求延长了心血管药物的核准时间
    • 影响心血管研发投资的财务永续性和盈利挑战

波特五力战略工具驾驭心血管药物市场

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解心血管药物市场的外部影响

外部宏观环境因素对心血管药物市场的表现动态起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解心血管治疗药物市场的竞争状况

对心血管治疗市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 心血管治疗市场定位矩阵供应商绩效评估

FPNV定位矩阵是评估心血管治疗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划心血管治疗药物市场的成功之路

心血管药物市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 心血管疾病的增加和人口老化正在推动对先进治疗的需求
      • 心血管治疗领域的技术进步与创新推动市场成长
      • 医疗成本上升和政府支持政策推动市场扩张
      • 对心血管疾病早期诊断和治疗的认识不断提高推动市场成长
    • 抑制因素
      • 患者和基层医疗提供者对心血管疾病及其治疗的认识和理解有限
      • 与心血管药物相关的副作用和不良反应使患者和医疗保健专业人员对引入新治疗方法犹豫不决。
    • 机会
      • 透过积极的全球行销策略扩大心血管疾病新基因疗法的覆盖范围
      • 利用人工智慧驱动的精准医疗改善复杂心血管疾病的治疗效果
      • 与生技公司建立策略伙伴关係，加速先锋心血管疗法的开发
    • 任务
      • 复杂的临床试验设计和严格的要求意味着心血管疾病药物的核准时间较长
      • 影响心血管研究和开发投资的财务永续性和盈利挑战
  • 市场区隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章按药物类别分類的心血管药物市场

  • 抗高血压药
    • β受体阻断剂
    • 钙离子通道阻断剂
    • 肾素-血管收缩素系统抑制剂
      • ACE抑制剂
      • 血管收缩素II受体阻断剂
  • 抗血栓药
    • 抗凝血物
    • 抗血小板药
    • 溶栓剂
  • 降血脂药
    • 贝特类
    • 烟碱酸
    • 他汀类药物

第七章依适应症分類的心血管药物市场

  • 心绞痛
  • 心臟衰竭
  • 高血脂症
  • 高血压
  • 心肌梗塞
  • 中风

第八章心血管药物市场患者细分

  • 成人用
  • 老年病
  • 小儿科

第九章心血管药物市场：依最终用户分类

  • 诊所
  • 紧急服务
  • 家庭护理设置
  • 医院

第十章心血管药物市场：依给药途径

  • 口服
  • 胃肠外的
    • 肌肉注射
    • 静脉
  • 经皮的

第十一章心血管药物市场：按分销管道

  • 医院药房
  • 网路药房
  • 零售药房

第十二章美洲心血管药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十三章亚太地区心血管药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十四章欧洲、中东和非洲心血管药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十五章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议
Product Code: MRR-1A1A064C02DF

The Cardiovascular Therapeutics Market was valued at USD 47.37 billion in 2023, expected to reach USD 50.71 billion in 2024, and is projected to grow at a CAGR of 7.48%, to USD 78.51 billion by 2030.

The cardiovascular therapeutics market encompasses a range of treatments and medications aimed at managing and mitigating heart and blood vessel disorders. With an increasing prevalence of cardiovascular diseases due to factors like aging populations, obesity, and lifestyle changes, the demand for effective therapeutics is burgeoning. The necessity for innovative treatments is amplified by rising global health awareness and advancements in medical technology, fostering applications across pharmaceuticals, surgical devices, and regenerative medicine. Key end-users include hospitals, clinics, research institutions, and pharmaceutical companies. Growth in this sector is primarily driven by technological advancements such as the development of novel therapeutics, personalized medicine, and the surge in minimally invasive procedures. Opportunities lie in the expansion of emerging markets where healthcare infrastructure is undergoing rapid development and in leveraging AI for predictive analytics and patient-specific treatment plans. Companies should focus on strategic partnerships and investments in R&D to capitalize on these trends. However, challenges such as high development costs, stringent regulatory environments, and potential side effects of some treatments can pose hurdles to growth. Another limitation is the lack of affordability and access to advanced healthcare services in certain regions, which can hinder widespread market penetration. Innovation opportunities include gene therapies, the use of big data analytics for patient profiling, and the development of bioabsorbable stents and smart wearable devices for monitoring cardiovascular health. The nature of the market is highly competitive and rapidly evolving, necessitating continuous innovation and adaptability from market players. Companies should focus on consumer education and conducting comprehensive clinical trials to ensure safety and efficacy, alongside developing cost-effective solutions to enhance global reach. By addressing these multifaceted challenges, businesses can position themselves at the forefront of the cardiovascular therapeutics market.

KEY MARKET STATISTICS
Base Year [2023] USD 47.37 billion
Estimated Year [2024] USD 50.71 billion
Forecast Year [2030] USD 78.51 billion
CAGR (%) 7.48%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cardiovascular Therapeutics Market

The Cardiovascular Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of cardiovascular diseases and aging population driving demand for advanced treatments
    • Technological advancements and innovation in cardiovascular therapeutics fostering market growth
    • Rising healthcare expenditure and supportive government policies boosting market expansion
    • Growing awareness about early diagnosis and treatment of cardiovascular conditions propelling market growth
  • Market Restraints
    • Limited awareness and understanding of cardiovascular diseases and their treatments among patients and primary care providers
    • Side effects and adverse reactions associated with cardiovascular therapeutics create hesitation among patients and healthcare providers to adopt new treatments
  • Market Opportunities
    • Expanding the reach of novel gene therapies for cardiovascular diseases through aggressive global marketing strategies
    • Leveraging AI-driven precision medicine to enhance treatment outcomes for complex cardiovascular conditions
    • Forming strategic collaborations with biotechnological firms to accelerate the development of pioneering cardiovascular drugs
  • Market Challenges
    • Complex clinical trial designs and stringent requirements leading to prolonged timeframes for cardiovascular drug approvals
    • Financial sustainability and profitability challenges impacting investments in cardiovascular research and development

Porter's Five Forces: A Strategic Tool for Navigating the Cardiovascular Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cardiovascular Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cardiovascular Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cardiovascular Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cardiovascular Therapeutics Market

A detailed market share analysis in the Cardiovascular Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cardiovascular Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cardiovascular Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cardiovascular Therapeutics Market

A strategic analysis of the Cardiovascular Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cardiovascular Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Amgen Inc., AstraZeneca plc, Bayer AG, Biotronik SE & Co. KG, Boston Scientific Corporation, Bristol-Myers Squibb Company, C. R. Bard, Inc., Cardinal Health, Inc., Edwards Lifesciences Corporation, Getinge AB, GlaxoSmithKline plc, Johnson & Johnson, Medtronic plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Terumo Corporation, and Zimmer Biomet Holdings, Inc..

Market Segmentation & Coverage

This research report categorizes the Cardiovascular Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Antihypertensive Drugs, Antithrombotic Drugs, and Lipid-Lowering Drugs. The Antihypertensive Drugs is further studied across Beta Blockers, Calcium Channel Blockers, and Renin-Angiotensin System Inhibitors. The Renin-Angiotensin System Inhibitors is further studied across ACE Inhibitors and Angiotensin II Receptor Blockers. The Antithrombotic Drugs is further studied across Anticoagulants, Antiplatelet Agents, and Thrombolytics. The Lipid-Lowering Drugs is further studied across Fibrates, Niacin, and Statins.
  • Based on Indication, market is studied across Angina Pectoris, Heart Failure, Hyperlipidemia, Hypertension, Myocardial Infarction, and Stroke.
  • Based on Patient Demographics, market is studied across Adult, Geriatric, and Pediatric.
  • Based on End-User, market is studied across Clinics, Emergency Services, Homecare Settings, and Hospitals.
  • Based on Route of Administration, market is studied across Oral, Parenteral, and Transdermal. The Parenteral is further studied across Intramuscular and Intravenous.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cardiovascular diseases and aging population driving demand for advanced treatments
      • 5.1.1.2. Technological advancements and innovation in cardiovascular therapeutics fostering market growth
      • 5.1.1.3. Rising healthcare expenditure and supportive government policies boosting market expansion
      • 5.1.1.4. Growing awareness about early diagnosis and treatment of cardiovascular conditions propelling market growth
    • 5.1.2. Restraints
      • 5.1.2.1. Limited awareness and understanding of cardiovascular diseases and their treatments among patients and primary care providers
      • 5.1.2.2. Side effects and adverse reactions associated with cardiovascular therapeutics create hesitation among patients and healthcare providers to adopt new treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Expanding the reach of novel gene therapies for cardiovascular diseases through aggressive global marketing strategies
      • 5.1.3.2. Leveraging AI-driven precision medicine to enhance treatment outcomes for complex cardiovascular conditions
      • 5.1.3.3. Forming strategic collaborations with biotechnological firms to accelerate the development of pioneering cardiovascular drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Complex clinical trial designs and stringent requirements leading to prolonged timeframes for cardiovascular drug approvals
      • 5.1.4.2. Financial sustainability and profitability challenges impacting investments in cardiovascular research and development
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cardiovascular Therapeutics Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Antihypertensive Drugs
    • 6.2.1. Beta Blockers
    • 6.2.2. Calcium Channel Blockers
    • 6.2.3. Renin-Angiotensin System Inhibitors
      • 6.2.3.1. ACE Inhibitors
      • 6.2.3.2. Angiotensin II Receptor Blockers
  • 6.3. Antithrombotic Drugs
    • 6.3.1. Anticoagulants
    • 6.3.2. Antiplatelet Agents
    • 6.3.3. Thrombolytics
  • 6.4. Lipid-Lowering Drugs
    • 6.4.1. Fibrates
    • 6.4.2. Niacin
    • 6.4.3. Statins

7. Cardiovascular Therapeutics Market, by Indication

  • 7.1. Introduction
  • 7.2. Angina Pectoris
  • 7.3. Heart Failure
  • 7.4. Hyperlipidemia
  • 7.5. Hypertension
  • 7.6. Myocardial Infarction
  • 7.7. Stroke

8. Cardiovascular Therapeutics Market, by Patient Demographics

  • 8.1. Introduction
  • 8.2. Adult
  • 8.3. Geriatric
  • 8.4. Pediatric

9. Cardiovascular Therapeutics Market, by End-User

  • 9.1. Introduction
  • 9.2. Clinics
  • 9.3. Emergency Services
  • 9.4. Homecare Settings
  • 9.5. Hospitals

10. Cardiovascular Therapeutics Market, by Route of Administration

  • 10.1. Introduction
  • 10.2. Oral
  • 10.3. Parenteral
    • 10.3.1. Intramuscular
    • 10.3.2. Intravenous
  • 10.4. Transdermal

11. Cardiovascular Therapeutics Market, by Distribution Channel

  • 11.1. Introduction
  • 11.2. Hospital Pharmacies
  • 11.3. Online Pharmacies
  • 11.4. Retail Pharmacies

12. Americas Cardiovascular Therapeutics Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Cardiovascular Therapeutics Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Cardiovascular Therapeutics Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2023
  • 15.2. FPNV Positioning Matrix, 2023
  • 15.3. Competitive Scenario Analysis
  • 15.4. Strategy Analysis & Recommendation

LIST OF FIGURES

  • FIGURE 1. CARDIOVASCULAR THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. CARDIOVASCULAR THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 21. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. CARDIOVASCULAR THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 27. CARDIOVASCULAR THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CARDIOVASCULAR THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CARDIOVASCULAR THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ACE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY FIBRATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY NIACIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY STATINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANGINA PECTORIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY HYPERLIPIDEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY STROKE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY EMERGENCY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. BRAZIL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 86. BRAZIL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 89. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 90. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 91. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
  • TABLE 92. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 94. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 97. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. MEXICO CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. MEXICO CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 100. MEXICO CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 101. MEXICO CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 102. MEXICO CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
  • TABLE 103. MEXICO CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. MEXICO CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 105. MEXICO CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. MEXICO CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. MEXICO CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 108. MEXICO CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 110. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 111. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 112. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 113. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
  • TABLE 114. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 116. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 119. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. AUSTRALIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 135. AUSTRALIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 136. AUSTRALIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 137. AUSTRALIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
  • TABLE 138. AUSTRALIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. AUSTRALIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 140. AUSTRALIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. AUSTRALIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. AUSTRALIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 143. AUSTRALIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. CHINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 145. CHINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 146. CHINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 147. CHINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 148. CHINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
  • TABLE 149. CHINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 150. CHINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 151. CHINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. CHINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. CHINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 154. CHINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 155. INDIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 156. INDIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 157. INDIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 158. INDIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 159. INDIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
  • TABLE 160. INDIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 161. INDIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 162. INDIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. INDIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. INDIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 165. INDIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. INDONESIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 167. INDONESIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 168. INDONESIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 169. INDONESIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 170. INDONESIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
  • TABLE 171. INDONESIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 172. INDONESIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 173. INDONESIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. INDONESIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. INDONESIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 176. INDONESIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 177. JAPAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 178. JAPAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 179. JAPAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 180. JAPAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 181. JAPAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
  • TABLE 182. JAPAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 183. JAPAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 184. JAPAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 185. JAPAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. JAPAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 187. JAPAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 188. MALAYSIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 189. MALAYSIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 190. MALAYSIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 191. MALAYSIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 192. MALAYSIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
  • TABLE 193. MALAYSIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 194. MALAYSIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 195. MALAYSIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 196. MALAYSIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 197. MALAYSIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 198. MALAYSIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 199. PHILIPPINES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 200. PHILIPPINES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 201. PHILIPPINES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 202. PHILIPPINES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 203. PHILIPPINES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
  • TABLE 204. PHILIPPINES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 205. PHILIPPINES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 206. PHILIPPINES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 207. PHILIPPINES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. PHILIPPINES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 209. PHILIPPINES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 210. SINGAPORE CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 211. SINGAPORE CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 212. SINGAPORE CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 213. SINGAPORE CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 214. SINGAPORE CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
  • TABLE 215. SINGAPORE CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 216. SINGAPORE CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 217. SINGAPORE CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 218. SINGAPORE CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 219. SINGAPORE CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 220. SINGAPORE CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 221. SOUTH KOREA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 222. SOUTH KOREA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 223. SOUTH KOREA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 224. SOUTH KOREA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 225. SOUTH KOREA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
  • TABLE 226. SOUTH KOREA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 227. SOUTH KOREA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 228. SOUTH KOREA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 229. SOUTH KOREA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 230. SOUTH KOREA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 231. SOUTH KOREA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 232. TAIWAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 233. TAIWAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 234. TAIWAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 235. TAIWAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 236. TAIWAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
  • TABLE 237. TAIWAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 238. TAIWAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 239. TAIWAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 240. TAIWAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 241. TAIWAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 242. TAIWAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 243. THAILAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 244. THAILAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 245. THAILAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 246. THAILAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 247. THAILAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
  • TABLE 248. THAILAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 249. THAILAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 250. THAILAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 251. THAILAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 252. THAILAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 253. THAILAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 254. VIETNAM CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 255. VIETNAM CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 256. VIETNAM CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 257. VIETNAM CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 258. VIETNAM CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
  • TABLE 259. VIETNAM CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 260. VIETNAM CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 261. VIETNAM CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 262. VIETNAM CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 263. VIETNAM CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 264. VIETNAM CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 277. DENMARK CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 278. DENMARK CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 279. DENMARK CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 280. DENMARK CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 281. DENMARK CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
  • TABLE 282. DENMARK CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 283. DENMARK CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 284. DENMARK CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 285. DENMARK CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 286. DENMARK CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 287. DENMARK CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 288. EGYPT CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 289. EGYPT CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 290. EGYPT CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 291. EGYPT CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 292. EGYPT CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
  • TABLE 293. EGYPT CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 294. EGYPT CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 295. EGYPT CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 296. EGYPT CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 297. EGYPT CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 298. EGYPT CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 299. FINLAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 300. FINLAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 301. FINLAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 302. FINLAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 303. FINLAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MIL